無料プレビュー

Oruka Therapeutics, Inc. (ORKA) · NASDAQ Global Market

プロフィール

Oruka Therapeutics is a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for psoriasis and other inflammatory and immunology indications. The company's lead program, ORKA-001, targets IL-23p19 with extended half-life technology enabling infrequent dosing; its co-lead program, ORKA-002, targets IL-17A/F for psoriasis, hidradenitis suppurativa, and psoriatic arthritis. Oruka operates a focused development strategy in dermatologic and inflammatory diseases, with programs in clinical and preclinical stages. The company licenses its technology from Paragon Therap

主要指標

株価: $77.28 (-2.79%)
時価総額: 47億ドル
PER（今期予想）: -32.1
PBR: 4.4
配当利回り: —
52週レンジ: $24.31 – $115.52
業種: Healthcare / Biotechnology
上場: NASDAQ Global Market
構成銘柄: —

比較会社: VRTX Vertex Pharmaceuticals Incorporated、MRNA Moderna, Inc.、REGN Regeneron Pharmaceuticals, Inc.、ARGX argenx SE、SGEN Seagen Inc.、RVMD Revolution Medicines, Inc.、ONC BeOne Medicines AG、ALNY Alnylam Pharmaceuticals, Inc.

長期トレンド・直近動向・強気／弱気シナリオ・業績10年・バリュエーション・テクニカル・株主・役員・深掘り分析は会員向けです。

7日間無料で全文を読むログイン

次回決算: 2026-11-11 · 更新: 2026-10-09